<!doctype html><html lang=en-us><head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=1313&amp;path=livereload" data-no-instant defer></script><meta charset=utf-8><meta http-equiv=X-UA-Compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1,shrink-to-fit=no"><meta http-equiv=Content-Security-Policy content="default-src 'self'; script-src 'self' 'unsafe-inline' https://gc.zgo.at https://cdn.jsdelivr.net; style-src 'self' 'unsafe-inline'; img-src 'self' data: https:; font-src 'self' data:; connect-src 'self' https://philippdubach.goatcounter.com https://weekly-top-goatcounter-api.philippd.workers.dev https://gc.zgo.at https://pdub.click; frame-ancestors 'self'; base-uri 'self';"><link rel=preconnect href=https://gc.zgo.at crossorigin><link rel=preconnect href=https://static.philippdubach.com crossorigin><link rel=preconnect href=https://pdub.click crossorigin><link rel=dns-prefetch href=https://gc.zgo.at><link rel=dns-prefetch href=https://static.philippdubach.com><link rel=dns-prefetch href=https://pdub.click><meta name=robots content="index, follow"><title>Google Discovers New Cancer Therapy Pathway - philippdubach.com</title><meta name=description content="Google releases C2S-Scale 27B, an AI model that discovered a cancer therapy pathway by identifying drugs making tumors visible to immunity."><meta name=keywords content="C2S-Scale 27B,Gemma AI model,cancer immunotherapy,cold tumors,hot tumors,antigen presentation,silmitasertib,CK2 inhibitor,interferon,single-cell analysis,virtual drug screening,Google DeepMind,Yale University collaboration,foundation model,therapeutic discovery"><meta name=author content="Philipp Dubach"><meta name=generator content="Hugo 0.149.0"><link rel=canonical href=http://localhost:1313/2025/10/18/google-discovers-new-cancer-therapy-pathway/><style>*{margin:0;padding:0;box-sizing:border-box}.visually-hidden{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);white-space:nowrap;border:0}body{font-family:helvetica neue,Helvetica,Arial,segoe ui,sans-serif;padding-top:90px;line-height:1.6;color:#333;background-color:#ffff}blockquote{margin:1em 0;padding-left:1em;border-left:2px solid #ccc;color:#666}blockquote p{margin:.5em 0}.container{display:flex;max-width:1200px;margin:0 auto;min-height:100vh}.sidebar{width:200px;background-color:#ffff;padding:1.5rem;border-right:0 solid #e9ecef;position:sticky;top:0;height:100vh;overflow-y:auto}.site-title a{text-decoration:none;color:#333;font-size:1.5rem;font-weight:700}.site-description{color:#666;margin:.5rem 0 2rem;font-size:.9rem}.navigation ul{list-style:none;margin-bottom:2rem}.navigation li{margin-bottom:.5rem}.navigation a{text-decoration:none;color:#007acc;font-weight:500}.navigation a:hover{text-decoration:underline}.social-links a{display:inline-block;margin-right:1rem;color:#666;text-decoration:none;font-size:.9rem}.social-links a:hover{color:#007acc}.content{flex:1;padding:2rem;padding-bottom:3rem;max-width:800px}.posts{max-width:90%}.post{margin-bottom:1rem;padding-bottom:1rem}.post:last-child{border-bottom:none}.post-title{margin-bottom:.5rem;line-height:1.3}.post-title a{text-decoration:none;color:#333;font-size:1.25rem;font-weight:600;line-height:1.3}.post-title a:hover{color:#007acc}.post-meta{font-size:.85rem;color:#666;margin-bottom:0}.post-meta a{color:#007acc;text-decoration:none}.post-meta a:hover{text-decoration:underline}.post-content{line-height:1.7}.post-content p{margin-bottom:1rem}.post-content p:last-child{margin-bottom:.5rem}.post-content a{color:#007acc;text-decoration:none}.post-content a:hover{text-decoration:underline}.project-tag{background-color:#e9ecef;color:#495057;padding:2px 6px;border-radius:3px;font-size:9px;font-weight:500;text-transform:uppercase;letter-spacing:.3px;margin-left:6px;display:inline-block;vertical-align:middle;border:1px solid #dee2e6}.archive{max-width:90%}.year h2{margin:2rem 0 1rem;color:#333;font-size:1.5rem}.archive-item{display:flex;margin-bottom:.75rem;align-items:baseline}.archive-meta{width:60px;flex-shrink:0;font-size:.85rem;color:#666}.archive-title{flex:1}.archive-title a{text-decoration:none;color:#333}.archive-title a:hover{color:#007acc}@supports(text-wrap:balance){.archive-title{text-wrap:balance}}.single .post-title{font-size:1.5rem;margin-bottom:1rem;line-height:1.3}.pagination{margin-top:2rem;margin-bottom:1rem;text-align:center;padding-top:2rem;padding-bottom:1rem;border-top:1px solid #e9ecef}.pagination a{color:#007acc;text-decoration:none;font-weight:500}.pagination a:hover{text-decoration:underline}.img-lightbox{cursor:pointer;transition:opacity .2s}.img-lightbox:hover{opacity:.9}.lightbox-overlay{display:none;position:fixed;top:0;left:0;width:100%;height:100%;background:#f8f9fa;z-index:9999;cursor:pointer;align-items:center;justify-content:center;padding:2rem;box-sizing:border-box}.lightbox-overlay:target{display:flex}.lightbox-overlay img{max-width:95%;max-height:95%;object-fit:contain;background:#f8f9fa}.feedback-footer{margin-top:.75rem;padding-top:.75rem;border-top:1px solid #e9ecef;text-align:center;color:#666;font-size:.9rem;margin-bottom:2rem}.feedback-footer p{margin:0;line-height:1.6}.feedback-footer a{color:#007acc;text-decoration:none}.feedback-footer a:hover{text-decoration:underline}@media screen and (max-width:768px){html{font-size:8px !important}body{font-size:1rem !important}.sidebar{width:100px !important;padding:.75rem !important}.container{max-width:600px !important;margin:0 20px !important}.content{max-width:400px !important;padding:1rem !important;padding-bottom:.5rem !important}.pagination{margin-bottom:1.5rem !important;padding-bottom:1.5rem !important}.project-tag{padding:1px 3px !important;border-radius:1.5px !important;font-size:4.5px !important;letter-spacing:.15px !important;margin-left:3px !important}.archive-meta{width:30px !important}.post-title,.post-title a,.single .post-title{line-height:1.2 !important}.post-content p:last-child{margin-bottom:.25rem !important}.feedback-footer{margin-top:.5rem !important;padding-top:.5rem !important;margin-bottom:1rem !important}}</style><link rel=icon type=image/png href=/icons/favicon-96x96.png sizes=96x96><link rel=icon type=image/svg+xml href=/icons/favicon.svg><link rel="shortcut icon" href=/icons/favicon.ico><link rel=apple-touch-icon sizes=180x180 href=/icons/apple-touch-icon.png><meta name=apple-mobile-web-app-title content="philippdubach.com"><link rel=manifest href=/icons/site.webmanifest><meta name=theme-color content="#2c3e50"><meta name=msapplication-TileColor content="#2c3e50"><meta property="og:title" content="Google Discovers New Cancer Therapy Pathway"><meta property="og:description" content="Google releases C2S-Scale 27B, an AI model that discovered a cancer therapy pathway by identifying drugs making tumors visible to immunity."><meta property="og:type" content="article"><meta property="og:url" content="http://localhost:1313/2025/10/18/google-discovers-new-cancer-therapy-pathway/"><meta property="og:site_name" content="philippdubach.com"><meta property="og:locale" content="en_US"><meta property="og:logo" content="http://localhost:1313/icons/favicon.ico"><meta property="og:image" content="https://static.philippdubach.com/ograph/ograph-CancerTherapy.jpg"><meta property="og:image:secure_url" content="https://static.philippdubach.com/ograph/ograph-CancerTherapy.jpg"><meta property="og:image:url" content="https://static.philippdubach.com/ograph/ograph-CancerTherapy.jpg"><meta property="og:image:type" content="image/jpeg"><meta property="article:published_time" content="2025-10-18T00:00:00Z"><meta property="article:modified_time" content="2025-10-18T00:00:00Z"><meta property="article:section" content="posts"><meta name=twitter:card content="summary_large_image"><meta name=twitter:title content="Google Discovers New Cancer Therapy Pathway"><meta name=twitter:description content="Google releases C2S-Scale 27B, an AI model that discovered a cancer therapy pathway by identifying drugs making tumors visible to immunity."><meta name=twitter:image content="https://static.philippdubach.com/ograph/ograph-CancerTherapy.jpg"><meta name=twitter:image:src content="https://static.philippdubach.com/ograph/ograph-CancerTherapy.jpg"><script type=application/ld+json>{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/localhost:1313\/"},{"@type":"ListItem","position":2,"name":"Posts","item":"http:\/\/localhost:1313\/posts/"},{"@type":"ListItem","position":3,"name":"Google Discovers New Cancer Therapy Pathway","item":"http:\/\/localhost:1313\/2025\/10\/18\/google-discovers-new-cancer-therapy-pathway\/"}]}</script><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","headline":"Google Discovers New Cancer Therapy Pathway","name":"Google Discovers New Cancer Therapy Pathway","description":"Google releases C2S-Scale 27B, an AI model that discovered a cancer therapy pathway by identifying drugs making tumors visible to immunity.","keywords":["C2S-Scale 27B","Gemma AI model","cancer immunotherapy","cold tumors","hot tumors","antigen presentation","silmitasertib","CK2 inhibitor","interferon","single-cell analysis","virtual drug screening","Google DeepMind","Yale University collaboration","foundation model","therapeutic discovery"],"articleBody":"\"Google gets a lot of scrutiny for some of their work in other domains; nevertheless, it\\u0026rsquo;s fair to appreciate that they continue to put major resources behind using AI to accelerate therapeutic discovery. The model and resources are open access and available to the research community.\\nHow C2S-Scale 27B works: A major challenge in cancer immunotherapy is that many tumors are \\u0026ldquo;cold\\u0026rdquo; — invisible to the body\\u0026rsquo;s immune system. A key strategy to make them \\u0026ldquo;hot\\u0026rdquo; is to force them to display immune-triggering signals through a process called antigen presentation. We gave our new C2S-Scale 27B model a task: Find a drug that acts as a conditional amplifier, one that would boost the immune signal only in a specific \\u0026ldquo;immune-context-positive\\u0026rdquo; environment where low levels of interferon (a key immune-signaling protein) were already present, but inadequate to induce antigen presentation on their own.\\nFrom their press release:\\nC2S-Scale generated a novel hypothesis about cancer cellular behavior and we have since confirmed its prediction with experimental validation in living cells. This discovery reveals a promising new pathway for developing therapies to fight cancer.\\nFor a 27B model, that\\u0026rsquo;s really really neat! And on a more general note, scaling seems to deliver:\\nThis work raised a critical question: Does a larger model just get better at existing tasks, or can it acquire entirely new capabilities? The true promise of scaling lies in the creation of new ideas, and the discovery of the unknown.\\nOn a more critical note, it would be interesting to see whether this model can perform any better than existing simple linear models for predicting gene expression interactions.\\nOriginal bioRxiv paper linked in this post\\u0026rsquo;s title.\\n\"","wordCount":276,"inLanguage":"en","image":"https:\/\/static.philippdubach.com\/ograph\/ograph-CancerTherapy.jpg","datePublished":"2025-10-18T00:00:00Z","dateModified":"2025-10-18T00:00:00Z","mainEntityOfPage":{"@type":"WebPage","@id":"http:\/\/localhost:1313\/2025\/10\/18\/google-discovers-new-cancer-therapy-pathway\/"},"publisher":{"@type":"Organization","name":"philippdubach","logo":{"@type":"ImageObject","url":"http:\/\/localhost:1313\/icons/favicon.ico"}},"author":{"@type":"Person","name":"Philipp Dubach"}}</script></head><body class=linkblog><div class=container><aside class=sidebar><div class=sidebar-content><div class=site-header><div class=site-title><a href=http://localhost:1313/>philippdubach</a></div><p class=site-description>Blog about Personal Projects, Articles and Papers on Economics, Finance and Technology</p></div><nav class=navigation><ul><li><a href=/>Home</a></li><li><a href=/projects/>Projects</a></li><li><a href=/posts/>Archive</a></li><li><a href=/about/>About</a></li><li><a href=/index.xml>RSS</a></li></ul></nav><div class=social-links><a href=https://github.com/philippdubach target=_blank rel=noopener>GitHub</a>
<a href=mailto:info@philippdubach.com>Email</a></div></div></aside><main class=content><article class="post single"><header class=post-header><h1 class=post-title>Google Discovers New Cancer Therapy Pathway</h1><div class=post-meta><time datetime=2025-10-18T00:00:00Z>October 18, 2025
</time>• 300 words
• 2 min read
• <a href=https://www.biorxiv.org/content/10.1101/2025.04.14.648850v3.full.pdf target=_blank rel=noopener>via</a>
• <a href=# id=share-link title="Copy short link" aria-label="Copy short link" style=text-decoration:none>∞</a>
<span id=share-status></span></div></header><div class=post-content><p>Google gets a lot of scrutiny for some of their work in other domains; nevertheless, it&rsquo;s fair to appreciate that they continue to put major resources behind using AI to accelerate therapeutic discovery. The <a href=https://huggingface.co/vandijklab/C2S-Scale-Gemma-2-27B>model</a> and <a href=https://github.com/vandijklab/cell2sentence>resources</a> are open access and available to the research community.</p><blockquote><p>How C2S-Scale 27B works: A major challenge in cancer immunotherapy is that many tumors are &ldquo;cold&rdquo; — invisible to the body&rsquo;s immune system. A key strategy to make them &ldquo;hot&rdquo; is to force them to display immune-triggering signals through a process called antigen presentation. We gave our new C2S-Scale 27B model a task: Find a drug that acts as a conditional amplifier, one that would boost the immune signal only in a specific &ldquo;immune-context-positive&rdquo; environment where low levels of interferon (a key immune-signaling protein) were already present, but inadequate to induce antigen presentation on their own.</p></blockquote><p>From their <a href=https://blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery/>press release</a>:</p><blockquote><p>C2S-Scale generated a novel hypothesis about cancer cellular behavior and we have since confirmed its prediction with experimental validation in living cells. This discovery reveals a promising new pathway for developing therapies to fight cancer.</p></blockquote><p>For a 27B model, that&rsquo;s really really neat! And on a more general note, scaling seems to deliver:</p><blockquote><p>This work raised a critical question: Does a larger model just get better at existing tasks, or can it acquire entirely new capabilities? The true promise of scaling lies in the creation of new ideas, and the discovery of the unknown.</p></blockquote><p>On a more critical note, it would be interesting to see whether this model can perform any better than existing simple linear models for predicting gene expression interactions.</p><p><em>Original bioRxiv paper linked in this post&rsquo;s title.</em></p></div></article><footer class=feedback-footer><p>Have feedback, comments, or ideas? <a href=mailto:info@philippdubach.com>I'd love to hear from you</a>.</p><p class=latest-post>Latest: <a href=/2025/12/27/book-review-why-machines-learn/>Book Review: Why Machines Learn</a></p><p class=most-read id=top-post-week style=min-height:1.5em></p></footer><script>(function(){var e,n,t=document.getElementById("top-post-week");if(t&&fetch("https://weekly-top-goatcounter-api.philippd.workers.dev").then(function(e){return e.ok?e.json():Promise.reject()}).then(function(e){if(e.hits&&e.hits.length>0){var n=e.hits[0];t.innerHTML='Most read: <a href="'+n.path+'">'+n.title.replace(" - philippdubach.com","")+"</a>"}else t.remove()}).catch(function(){t.remove()}),n=document.getElementById("share-link"),e=document.getElementById("share-status"),!n)return;n.addEventListener("click",function(t){t.preventDefault(),e.textContent="...";var s,n=window.location.href;navigator.clipboard&&navigator.clipboard.write&&typeof ClipboardItem!="undefined"?(s=new ClipboardItem({"text/plain":fetch("https://pdub.click/yourls-api.php?signature=4807288869&action=shorturl&format=json&url="+encodeURIComponent(n)).then(function(e){return e.json()}).then(function(e){var t=e.shorturl||"";return new Blob([t],{type:"text/plain"})}).catch(function(){return new Blob([""],{type:"text/plain"})})}),navigator.clipboard.write([s]).then(function(){e.textContent="url copied",setTimeout(function(){e.textContent=""},2e3)}).catch(function(){e.textContent="error",setTimeout(function(){e.textContent=""},2e3)})):fetch("https://pdub.click/yourls-api.php?signature=4807288869&action=shorturl&format=json&url="+encodeURIComponent(n)).then(function(e){return e.json()}).then(function(t){var n=t.shorturl;n&&navigator.clipboard&&navigator.clipboard.writeText?navigator.clipboard.writeText(n).then(function(){e.textContent="url copied",setTimeout(function(){e.textContent=""},2e3)}).catch(function(){e.textContent=n,setTimeout(function(){e.textContent=""},4e3)}):n?(e.textContent=n,setTimeout(function(){e.textContent=""},4e3)):(e.textContent="error",setTimeout(function(){e.textContent=""},2e3))}).catch(function(){e.textContent="error",setTimeout(function(){e.textContent=""},2e3)})})})()</script></main></div></body></html>